M
Maurice Perol
Researcher at Gdańsk Medical University
Publications - 6
Citations - 1708
Maurice Perol is an academic researcher from Gdańsk Medical University. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 3, co-authored 6 publications receiving 1222 citations.
Papers
More filters
Journal ArticleDOI
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Solange Peters,D. Ross Camidge,Alice T. Shaw,Shirish M. Gadgeel,Jin S. Ahn,Dong Wan Kim,Sai-Hong Ignatius Ou,Maurice Perol,Rafal Dziadziuszko,Rafael Rosell,Ali Zeaiter,Emmanuel Mitry,Sophie Golding,Bogdana Balas,Johannes Noe,Peter N. Morcos,Tony Mok +16 more
TL;DR: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK‐positive NSCLC and independent review committee–assessed progression‐free survival were consistent with those for the primary end point.
Journal ArticleDOI
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer
Laura Mezquita,Aurélie Swalduz,Cécile Jovelet,Sandra Ortiz-Cuaran,K. Howarth,David Planchard,V. Avrillon,Gonzalo Recondo,Solène Marteau,Jose Carlos Benitez,Frank de Kievit,Vincent Plagnol,Ludovic Lacroix,Luc Odier,Etienne Rouleau,Pierre Fournel,Caroline Caramella,Claire Tissot,Julien Adam,Samuel Woodhouse,Claudio Nicotra,Edouard Auclin,Jordi Remon,Clive Morris,Emma Green,Christophe Massard,Christophe Massard,Maurice Perol,Luc Friboulet,Benjamin Besse,Benjamin Besse,Benjamin Besse,Pierre Saintigny +32 more
TL;DR: Next-generation, targeted, amplicon-based sequencing for liquid biopsy specimen profiling provides clinically relevant detection of ALK/ROS1 fusions in TKI-naïve patients and allows for the identification of resistance mutations in patients treated with TKIs.
Second-line treatment options in Non-Small Cell Lung Cancer (NSCLC): report from an International Experts Panel Meeting of the Italian Association of Thoracic Oncology
Cesare Gridelli,P. Baas,Fabrice Barlesi,Fortunato Ciardiello,L. Crinò,Enriqueta Felip,Shirish M. Gadgeel,Vali Papadimitrakopoulou,Luis Paz-Ares,David Planchard,Maurice Perol,Nasser H. Hanna,Assunta Sgambato,Francesco Casaluce,Filippo de Marinis +14 more
TL;DR: In this paper, the second-line treatment of non-oncogene-addicted NSCLC patients is discussed and compared to first-line therapy for addicted as well as not -addicted non-small-cell lung cancer.
Proceedings ArticleDOI
Abstract 4581: Feasibility of an amplicon-based liquid biopsy forALKandROS1fusions in advanced non-small cell lung cancer (NSCLC) patients
Laura Mezquita,Yuebi Hu,K. Howarth,Cécile Jovelet,David Planchard,Ludovic Lacroix,Aurélie Swalduz,Sandra Ortiz-Cuaran,V. Avrillon,Vincent Plagnol,John F. Beeler,Katherine Baker-Neblett,Greg Jones,Nitzan Rosenfeld,Clive Morris,Emma Green,Edward S. Kim,Maurice Perol,Pierre Saintigny,Stephen V. Liu,Geoff R. Oxnard,Benjamin Besse +21 more
Journal ArticleDOI
Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
Orion Valet,Aurélie Swalduz,Maxime Boussageon,Adrien Buisson,V. Avrillon,Bénédicte Mastroianni,Maurice Perol +6 more
TL;DR: It is reported, for the first time, a case of a patient treated with this association, with a prolonged response on leptomeningeal metastasis, and a comprehensive overview of the available literature on the efficacy and tolerance of this association.